Showing results (11-20 of 67) with videos related to

Sort By:
Pageof 7
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 30, 2014
Cabozantinib overcomes crizotinib resistance in ROS1 fusion-positive cancerRyohei Katayama, Yuka Kobayashi, Luc Friboulet, et al.
Tumori|May 21, 2016
Crizotinib primary resistance overcome by ceritinib in a patient with ALK-rearranged non-small cell lung cancerFrancesco Facchinetti, Caroline Caramella, Nathalie Auger, et al.
Cancer Discovery|November 21, 2020
Clinicogenomic Analysis of FGFR2-Rearranged Cholangiocarcinoma Identifies Correlates of Response and Mechanisms of Resistance to PemigatinibIan M Silverman, Antoine Hollebecque, Luc Friboulet, et al.
British Journal of Cancer|January 4, 2024
Resistance to BRAF inhibition explored through single circulating tumour cell molecular profiling in BRAF-mutant non-small-cell lung cancerLaura Mezquita, Marianne Oulhen, Agathe Aberlenc, et al.
Neoplasia (New York, N.Y.)|October 28, 2008
Recurrent overexpression of c-IAP2 in EBV-associated nasopharyngeal carcinomas: critical role in resistance to Toll-like receptor 3-mediated apoptosisLuc Friboulet, Catherine Pioche-Durieu, Sandrine Rodriguez, et al.
JTO Clinical and Research Reports|February 24, 2025
Personalized Therapy in a Patient With EGFR-Mutated NSCLC Developing Sequential CCDC6-RET Fusion and BRAF V600E Mutation as Bypass Resistance MechanismsArianna Marinello, Claudia Parisi, Damien Vasseur, et al.
The Journal of Experimental Medicine|March 16, 2019
Secreted PD-L1 variants mediate resistance to PD-L1 blockade therapy in non-small cell lung cancerBo Gong, Kazuma Kiyotani, Seiji Sakata, et al.
Thyroid : Official Journal of the American Thyroid Association|September 12, 2023
Alkylating Agent-Induced High Tumor Mutational Burden in Medullary Thyroid Cancer and Response to Immune Checkpoint Inhibitors: Two Case ReportsSophie Moog, Livia Lamartina, Mohamed-Amine Bani, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 13, 2016
Crizotinib-Resistant ROS1 Mutations Reveal a Predictive Kinase Inhibitor Sensitivity Model for ROS1- and ALK-Rearranged Lung CancersFrancesco Facchinetti, Yohann Loriot, Mei-Shiue Kuo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 18, 2014
Two novel ALK mutations mediate acquired resistance to the next-generation ALK inhibitor alectinibRyohei Katayama, Luc Friboulet, Sumie Koike, et al.
Pageof 7